1642 / 1708
protocol that limited prospective follow-up to 5 years and
included patients with high-risk features. There are a number
of clinical factors that strongly influence baseline and longi-
tudinal cognition, including the effects of age
(28) ,tumor
(hydrocephalus), and surgery
(29, 30). Accounting for these
factors and the development of comprehensive parametric
models, including dose, requires more patients.
In summary, there are strong associations between ra-
diation dose, irradiated volume, and cognitive outcomes as
measured by standardized tests. When modeling the effect
of radiation dose, clinical factors that affect baseline and
longitudinal measures should be considered. Future
research should be focused on assessing larger datasets,
inclusion of patients treated with a wider range of CSI dose,
and the development of multiparametric models.
References
1.
Silverman CL, Palkes H, Talent B, et al. Late effects of radiotherapy on patients with cerebellar medulloblastoma. Cancer 1984;54:825-829.
2.
LeBaron S, Zeltzer PM, Zeltzer LK, et al. Assessment of quality of survival in children with medulloblastoma and cerebellar astrocytoma. Cancer 1988;62:1215-1222.
3.
Hoppe-Hirsch E, Renier D, Lellouch-Tubiana A, et al. Medulloblas- toma in childhood: Progressive intellectual deterioration. Childs Nerv Syst 1990;6:60-65.
4.
Kao GD, Goldwein JW, Schultz DJ, et al. The impact of perioperative factors on subsequent intelligence quotient deficits in children treated for medulloblastoma/posterior fossa primitive neuroectodermal tu- mors. Cancer 1994;74:965-971.
5.
Radcliffe J, Bunin GR, Sutton LN, et al. Cognitive deficits in long- term survivors of childhood medulloblastoma and other noncortical tumors: Age-dependent effects of whole brain radiation. Int J Dev Neurosci 1994;12:327-334.
6.
Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. J Clin Oncol 1999;17:2127-2136 .7.
Merchant TE, Kun LE, Krasin MJ, et al. Multi-institution prospective trial of reduced-dose craniospinal radiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensitive chemotherapy for average-risk medullo- blastoma. Int J Radiat Oncol Biol Phys 2008;70:782-787 .8. Gajjar A. A Clinical and Molecular Risk-Directed Therapy for Newly
Diagnosed Medulloblastoma. NCT01878617 (SJMB03).
ClinicalTrial s.gov2013. Available from: URL:
http://clinicaltrials.gov/ct2/show/ NCT01878617?term Z sjmb03&rank Z 1. Accessed July 24, 2014.
9. Michalski J. A study evaluating limited target volume boost irradiation
and reduced dose craniospinal radiotherapy (18.00 Gy) and
chemotherapy in children with newly diagnosed standard risk me-
dulloblastoma: A phase III double randomized Trial.
ClinicalTrials. govidentifier NCT00085735 (ACNS0331). Available at:
http:// clinicaltrials.gov/ct2/show/NCT00085735?term Z acns0331&rank Z 1.
10.
Ris MD, Packer R, Goldwein J, et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for me- dulloblastoma: A Children’s Cancer Group study. J Clin Oncol 2001; 19:3470-3476.
11.
Walter AW, Mulhern RK, Gajjar A, et al. Survival and neuro- developmental outcome of young children with medulloblastoma at St. Jude Children’s Research Hospital. J Clin Oncol 1999;17:3720- 3728.
12.
Armstrong GT, Jain N, Liu, et al. Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. Neuro Oncol 2010;12:1173-1186.
13.
Merchant TE, Kiehna EN, Li C, et al. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys 2006;65:210-221.
14.
Monje ML, Vogel H, Masek M, et al. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol 2007;62:515-520.
15.
Lawrence YR, Li XA el NI, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S20-S27 .16.
Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted cranio- spinal radiotherapy followed by high-dose chemotherapy and stem- cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96); long-term results from a prospective, multicentre trial. Lancet Oncol 2006;7:813-820.
17.
Wechsler D. Wechsler Preschool and Primary Scale of Intelligence. Revised (WPPSI-R). San Antonio, TX: Psychological Corporation; 1989 .18.
Wechsler D. Wechsler Intelligence Scale for Children (WISC-III). 3rd ed. New York: Psychological Corporation; 1991.
19.
Wechsler D. Wechsler Adult Intelligence Scale. New York: Psycho- logical Corporation; 1981. Revised (WAIS-Revised) .20.
Sattler JH. Assessment of Children. 3rd ed. San Diego, CA: Jerome M. Sattler; 1992219-243 .21.
Wechsler D. Wechsler Individual Achievement Test. New York: Psy- chology Corporation; 1992.
22.
Edelstein K, Spiegler BJ, Fung S, et al. Early aging in adult survivors of childhood medulloblastoma: Long-term neurocognitive, functional, and physical outcomes. Neuro Oncol 2011;13:536-545.
23.
Massimino M, Cefalo G, Riva D, et al. Long-term results of combined preradiation chemotherapy and age-tailored radio- therapy doses for childhood medulloblastoma. J Neurooncol 2012;108:163-171 .24.
Gupta T, Jalali R, Goswami S, et al. Early clinical outcomes demonstrate preserved cognitive function in children with average-risk medulloblastoma when treated with hyperfractionated radiation ther- apy. Int J Radiat Oncol Biol Phys 2012;83:1534-1540 .25. Gajjar A. A Clinical and Molecular Risk-Directed Therapy for Newly
Diagnosed Medulloblastoma. NCT01878617.
ClinicalTrials.gov2013.
Available from: URL:
http://clinicaltrials.gov/ct2/results?term Z sjmb 12. Accessed July 24, 2014.
26.
Merchant TE. Clinical controversies: Proton therapy for pediatric tu- mors. Semin Radiat Oncol 2013;23:97-108.
27.
Merchant TE. Proton beam therapy in pediatric oncology. Cancer J 2009;15:298-305.
28.
Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004;5:399-408.
29.
Di Rocco C, Chieffo D, Pettorini BL, et al. Preoperative and post- operative neurological, neuropsychological and behavioral impairment in children with posterior cranial fossa astrocytomas and medullo- blastomas: The role of the tumor and the impact of the surgical treatment. Childs Nerv Syst 2010;26:1173-1188.
30.
Palmer SL, Hassall T, Evankovich K, et al. Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. Neuro Oncol 2010;12:1311-1317.
Volume 90 Number 3 2014
Radiation effects in medulloblastoma
561